Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline

Fig. 4

Association of plasma Aβ42/Aβ40 with episodic memory performance. Participants were classified as plasma Aβ42/Aβ40(+) or Aβ42/Aβ40(−) by applying a cutoff of 0.241 corresponding to the maximum Youden index. A, B Distribution of S-FNAME total score (A) and SFN-N composite score (B) between Aβ42/Aβ40(−) and Aβ42/Aβ40(+) groups. Cognitive scores were compared between Aβ42/Aβ40(−) and Aβ42/Aβ40(+) groups using Mann-Whitney test. * P < .05; *** P < .001. Horizontal line depicts median and whiskers depict interquartile range. C, D Correlations between Aβ42/Aβ40 and S-FNAME total score (C) and SFN-N composite (D) score. Solid blue line represents the regression line; dashed lines represent 95% confidence interval

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193